Posted by Michael Wonder on 16 Dec 2019
Proposal to widen funded access to lenalidomide for multiple myeloma
16 December 2019 - PHARMAC is seeking feedback on a proposal to widened funded access to lenalidomide (Revlimid) to include maintenance treatment for people with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant (auto-SCT), through a provisional agreement with Celgene.
In summary, the proposal would result in the following changes from 1 April 2020:
- lenalidomide (Revlimid) would be funded as maintenance treatment for people with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant.
- a new 5 mg capsule strength of lenalidomide would be funded, to make dosage adjustments easier for any of the funded indications.
Lenalidomide would continue to be funded for all the existing funded multiple myeloma indications.
